Introduction

Development of anti-cancer therapy has been an important issue for several decades [1], [2]. Treatment with anti-cancer agents is one of the most widely utilized modes of anti-tumor therapy. Various anti-cancer agents have been developed, including 5-fluoro-uracil (5-FU) [3]. Mechanistically, anti-cancer agents have been reported to cause apoptosis of cancer cells, which induces the initiation of anti-cancer immune responses [4]. In the host immune system, dendritic cells (DCs) appear to play a key role in anti-tumor activity. DCs recognize and uptake tumor antigens, and present the processed antigens on major histocompatibility complex molecules [5], [6], [7]. Thus, DCs can stimulate T lymphocytes, resulting in cytotoxic T lymphocyte activity. DCs also secrete several cytokines which are important in efficient anti-tumor activity [7].

WKYMVm was identified as an immune-stimulating synthetic peptide from a peptide library screening [8], [9]. WKYMVm stimulates leukocytic cells such as monocytes, neutrophils, natural killer (NK) cells, and DCs [9], [10], [11], [12]. Because of monocyte and neutrophil stimulation, chemotactic migration, superoxide anion production, and the production of certain inflammatory mediators such as leukotriene B4 is induced by WKYMVm [9], [13], [14]. NK cell stimulation with WKYMVm results in cytolytic activity and chemotactic migration [11]. The peptide stimulated chemotactic migration of DCs [12]. Three members of the formyl peptide receptor (FPR) family have been reported to be cognitive cell surface receptors for WKYMVm in humans [15], [16]. Mouse FPR has also been reported to act as a WKYMVm receptor [17]. Although WKYMVm has been reported to stimulate leukocytes which play important roles against cancer antigens, little is known about the role of WKYMVm in anti-cancer activity.

Combined administration of certain molecules can induce effective anti-cancer activity. Although various anti-cancer agents or anti-cancer therapies have been reported, development of new anti-cancer therapies which are effective and specific with low toxicity is still necessary. In this study we investigated the therapeutic activity of WKYMVm when it was administrated with an anti-cancer agent (5-FU) and a natural vaccine adjuvant (mature DCs, mDCs). The mechanism of action of the triple combination therapy was also characterized.
Results

Combined administration of WKYMVm, 5-FU, and mDCs causes anti-tumor activity in heterotopic cancer animal model

The putative anti-tumor activity of WKYMVm, 5-FU, or mDCs was examined. WKYMVm, 5-FU, or mDCs were first administered singly. For example, as shown in Fig. 1A, WKYMVm (100 μg/head) was injected four times at 12 h intervals. Single administration caused a slight decrease in tumor volume (Fig. 1B). When the agents were tested in pairs (WKYMVm+5-FU; WKYMVm+mDCs; mDCs+5-FU) against an animal model, anti-tumor activity was enhanced (Fig. 1B). The presence of 5-FU appeared to further potentiate anti-tumor activity (Fig. 1B, 5-FU+WKYMVm and 5-FU+mDCs). Moreover, when the triple combination (WKYMVm+5-FU+mDCs) was administered to the heterotopic cancer animal model, the most potent anti-tumor activity was observed (Fig. 1B).

Combined administration of WKYMVm, 5-FU, and mDCs elicits tumor apoptosis

Since tumor apoptosis is closely related to anti-tumor activity, the effect of each administration on tumor apoptosis was measured. As shown in Fig. 2, single administration of WKYMVm, 5-FU, or mDCs induced low levels of tumor cell death, and double combinations showed further increase in cell death, with the triple combination resulting in dramatically increased tumor cell death in the heterotopic cancer animal model (Fig. 2). The TUNEL-positive cells coincided with FAS expression, indicating that the tumor cell death observed is due to apoptosis (Fig. 2). Caspase-3 activity upon treatment was determined by immunofluorescence staining using anti-phospho-caspase-3 antibody. Consistent with the TUNEL staining and FAS expression results, caspase-3 activation increased as the number of combined agents increased, with the WKYMVm+5-FU+mDCs triple combination inducing a dramatic increase in caspase-3 activity (Fig. 2). The levels of tumor cell apoptosis and caspase-3 activity correlate well with the tumor volume data in Fig. 1B.

Figure 1. Anti-tumor activity of WKYMVm, 5-FU, and mature DCs in a heterotopic cancer animal model. (A) Protocol for the study of anti-tumor activity of WKYMVm, 5-FU, and mDCs. (B) The triple combination of WKYMVm, 5-FU, and mDCs has the most potent anti-tumor activity. CT-26 cells (5×10^5 cells in 100 μl of PBS) were injected s.c. into the right flank of Balb/c mice (n = 8) on day – 3. The mice were treated according to the protocol in (A). Tumor volume was measured and the data are shown as the mean ± SEM (n = 8). ***, P<0.001 compared with the control.
Administration of the triple combination causes the recruitment of CD8 T cells and NK cells into the tumor

To initiate an anti-tumor immune response, leukocytic cells need to be recruited into the tumor area [18]. Since administration of the triple combination (WKYMVm+5-FU+mDCs) elicited potent anti-tumor activity against the heterotopic cancer animal model, we examined what types of cells are recruited into the tumor by immunohistochemistry using anti-CD3, anti-CD4, anti-CD8, anti-CD11b, or anti-DX5 antibody. Administration of the triple combination caused dramatic recruitment of CD8 T lymphocytes and NK cells into the tumor area, as well as slight recruitment of CD4 T lymphocytes (Fig. 3A). Administration of anti-CD8 monoclonal antibody prior to the triple combination caused dramatic inhibition of CD8 T lymphocyte recruitment into the tumor area, without affecting NK cell recruitment (Fig. 3B). When anti-asialoGM1 antibody was administered prior to injection of the triple combination, NK cell recruitment into the tumor area was strongly blocked, but CD8 T lymphocyte recruitment was not affected (Fig. 3D). Anti-CD4 antibody administration prior to injection of the triple combination did not affect CD0 T lymphocyte or NK cell recruitment (Fig. 3C).

CD8 T cells and NK cells play major roles in the anti-tumor activity of the triple combination therapy

For efficient activation of anti-cancer activity in an experimental animal, several leukocyte types communicate with each other and act concertedly. We examined the relative contribution of individual leukocyte types on the anti-tumor activity induced by the triple combination therapy, by administrating antibodies against each leukocyte. When anti-CD8 antibody was administered to the heterotopic cancer animal model, the anti-tumor activity of the triple combination was almost completely inhibited (Fig. 4A). Administration of anti-asialoGM1 antibody elicited partial inhibition of the anti-tumor activity of the triple combination therapy (Fig. 4B). However, administration of the anti-CD4 antibody did not affect the anti-tumor activity of the triple combination (data not shown). These results indicate that CD8 T cells and NK cells play major roles in the anti-tumor activity of the triple combination of WKYMVm, 5-FU, and mDCs.

Administration of the WKYMVm, 5-FU, and mDCs triple combination elicits a change of cytokine profile in a heterotopic cancer animal model

We tested whether administration of WKYMVm, 5-FU, and mDCs in various combinations causes changes in cytokine profile compared to the control tumor lysate. As shown in Fig. 5A, administration of the triple combination caused dramatic changes in the levels of IFN-γ and IL-12 produced from tumor lysates in the heterotopic cancer animal model. The production of IFN-γ in the tumor gradually increased as the number of combined agents increased, with double combinations generally showing more IFN-γ production than single administration, and the triple combination showing the highest level of IFN-γ production (Fig. 5A). When IL-12 levels were measured, we found that single administration of each agent did not induce production of IL-12, and among the double combinations, only the combination of WKYMVm+mDCs enhanced IL-12 production in the animal model (Fig. 5B). Administration of the triple combination (WKYMVm+mDCs+5-FU) dramatically increased IL-12 production to a level that was two-fold higher than the WKYMVm+mDCs double combination (Fig. 5B).

Administration of the triple combination was also observed to enhance the production of IFN-γ and IL-12 in the peripheral blood (Fig. 5C–5F). To examine the role of CD8 T lymphocytes...
and NK cells in the production of these two cytokines upon triple combination administration, anti-CD8 or anti-asialoGM1 antibody was administered prior to triple combination treatment. Administration of anti-CD8 or anti-asialoGM1 antibody blocked triple combination-induced IFN-γ and IL-12 production in the peripheral blood (Fig. 5C–5F). These results indicate that CD8 T lymphocytes and NK cells play a role in IFN-γ and IL-12 production induced by triple combination treatment.

Anti-metastasis activity of combined administration of WKYMVm, 5-FU, and mDCs

When developing an effective anti-tumor therapeutic agent, it is important to develop agents which inhibit tumor recurrence [19]. The metastatic ability of cancer cells to migrate from their origin to other target tissues is one of the major reasons that make it difficult to develop an efficient anti-cancer agent [20], [21]. In our heterotopic cancer animal model, we observed that subcutaneous inoculation of CT-26 colon cancer cells caused spontaneous metastasis of the cells into the lung tissue (Fig. 6A). Administration of the triple WKYMVm+mDCs+5-FU combination almost completely blocked metastasis of colon cancer cells to the lungs (Fig. 6A). This triple combination-induced anti-metastasis activity was blocked by the administration of anti-CD8 or anti-asialoGM1 antibody (Fig. 6A), indicating that the anti-metastasis activity is mediated by CD8 T lymphocyte and NK cell activity.

We also used an artificial metastasis animal model to test the effect of different combinations of WKYMVm, 5-FU, and mDCs against metastasis. Injection of CT-26 colon cancer cells into the tail vein causes metastasis into the lungs. Lungs were isolated 14 days after CT-26 cell injection. Dramatic lung metastasis was observed with vehicle treated mice (Fig. 6B). Single or double combinations of WKYMVm, mDCs, and 5-FU inhibited tumor metastasis to varying degrees to reduce lung metastasis, and the most potent effect was observed with the triple combination (Fig. 6B).

Combined administration of WKYMVm, 5-FU, and mDCs enhances survival rates in a heterotopic cancer animal model

The survival rate of the heterotopic cancer animal model upon combined treatment was examined. We tested the combinations that showed relatively high anti-tumor activity in our previous assays above; 5-FU alone, 5-FU+WKYMVm, 5-FU+mDCs, and 5-FU+mDCs+WKYMVm. Administration of 5-FU alone, 5-FU+mDCs, or 5-FU+WKYMVm only slightly increased survival rate, but administration of the triple 5-FU+mDCs+WKYMVm combination strongly enhanced survival rate (Fig. 7A). All mice in the control group were died after 65 days, whereas 80% of the triple combination-administered group was alive at 80 days (Fig. 7A).

To test if adoptive transfer of CD8 T lymphocytes and NK cells could enhance the triple combination-induced survival of the heterotopic cancer animal model mice, we inoculated an increased number of colon cancer cells (1×10^6 cells/head) into mice. In this case, we observed improved survival of the triple combination-administered group (Fig. 7B). These results indicate that the combination of anti-tumor activity and adoptive transfer of immune cells can be used as an effective therapeutic strategy.
According to previous reports, IFN-γ, caspase-3 activity, and TUNEL staining results (Figs. 1 and 2). Measurement results were correlated well with FAS expression, dramatically inhibited tumor growth (Fig. 1). The tumor volume of CD8 T lymphocytes and NK cells can enhance the survival rate induced by the combination in the heterotopic cancer animal model. In this study, only certain combinations, namely WKYMVm+mDCs and the triple combination could induce IL-12 expression in the heterotopic cancer animal model (Fig. 5B). Single administration of WKYMVm or mDCs did not induce IL-12 production (Fig. 5B). This suggests that the stimulation of mDCs with WKYMVm is responsible for efficient induction of IL-12 in the animal model. Since WKYMVm is a ligand for the FPR family, it appears likely that the activation of the FPR family induces IL-12 expression from mDCs. In the survival rate experiment, triple administration of WKYMVm+5-FU+mDCs induced a strong enhancement of survival rate in a heterotopic cancer animal model, but 5-FU+mDCs treatment had a much lesser effect (Fig. 7). Since IL-12 production is strongly induced by the triple combination but not by 5-FU+mDCs (Fig. 5B), it may be possible that the triple combination enhances survival rate by stimulating the production of soluble factors such as IL-12.

Discussion

In this study, we demonstrated that administration of the triple combination of the synthetic peptide WKYMVm, mDCs, and 5-FU endows potent anti-cancer immunity. Single (WKYMVm, mDCs, or 5-FU) or double (WKYMVm+mDCs, 5-FU+WKYMVm or 5-FU+mDCs) treatment of mice slightly decreased tumor volume, but administration of the triple combination dramatically inhibited tumor growth (Fig. 1). The tumor volume measurement results were correlated well with FAS expression, caspase-3 activity, and TUNEL staining results (Figs. 1 and 2). According to previous reports, IFN-γ is known to induce the expression of cell death receptors such as FAS [22], [23]. In this study, we showed that the administration of different combinations of WKYMVm, 5-FU, or mDCs can induce IFN-γ expression, with the triple combination causing the most enhanced IFN-γ production (Fig. 5A). The expression level of IFN-γ was well correlated with the anti-tumor activity of each combination, suggesting that IFN-γ induced by the administration of each agent or combination is critically involved in anti-tumor activity in the animal model.

IL-12 can prime or stimulate CD8 T cells, CD8 T cells and NK cells [24], [25], [26]. In this study, only certain combinations, namely WKYMVm+mDCs and the triple combination could induce IL-12 expression in the heterotopic cancer animal model (Fig. 5B). Single administration of WKYMVm or mDCs did not induce IL-12 production (Fig. 5B). This suggests that the stimulation of mDCs with WKYMVm is responsible for efficient induction of IL-12 in the animal model. Since WKYMVm is a ligand for the FPR family, it appears likely that the activation of the FPR family induces IL-12 expression from mDCs. In the survival rate experiment, triple administration of WKYMVm+5-FU+mDCs induced a strong enhancement of survival rate in a heterotopic cancer animal model, but 5-FU+mDCs treatment had a much lesser effect (Fig. 7). Since IL-12 production is strongly induced by the triple combination but not by 5-FU+mDCs (Fig. 5B), it may be possible that the triple combination enhances survival rate by stimulating the production of soluble factors such as IL-12.

NK and CD8 T cells were recently reported to be important in cancer regression [27], [28], [29]. Here, we demonstrated that CD8 T and NK cells were enriched in tumors when the triple combination was administered (Fig. 3), and depletion of CD8 T cells or NK cells increased tumor growth (Fig. 4). In addition, depletion of CD8 T cells or NK cells reduced the levels of induced IFN-γ and IL-12 (Fig. 5C–5F). These results indicate that CD8 T cells and NK cells are involved in the anti-tumor effect of the triple combination. Triple administration of WKYMVm, mDCs and 5-FU also elicited an anti-metastasis effect in a heterotopic cancer animal model (Fig. 6). Intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes was shown to enhance the growth inhibition of metastatic lung tumors in mice [30], supporting our notion that IL-12 production may be associated with anti-metastasis activity of the triple combination.

In conclusion, triple combination immunotherapy with mDCs, the synthetic peptide WKYMVm, and 5-FU was superior to single or double treatment in inhibiting established primary tumors and metastasis, as well as prolonging survival. The increase in therapeutic efficacy was due to effects that occurred locally (enhanced levels of FAS and caspase-3 expression) and systemically (increased production of IFN-γ and IL-12). Therefore, use of
the triple combination therapy may have implications in solid tumor and metastasis treatment.

Materials and Methods

Mice

The Institutional Review Committee for Animal Care and Use at Dong-A University specifically approved this study (approval ID: DIACUC 07-6). Balb/c mice (males, 6–8 weeks old) were obtained from the Jackson Laboratory.

Cell culture and material

CT-26 cells (CRL-2638; ATCC American Type Culture Collection) are a colon adenocarcinoma cell line derived from Balb/c mice. CT-26 cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum and antibiotics at 37°C in a 5% CO2 humidified incubator. The synthetic peptide, WKYMVm, was synthesized at Anygen (Kwangju, Korea). The purity of synthesized WKYMVm was >98%. 5-FU was purchased from Choongwae, Pharma Co. (Seoul, Korea).
DC preparation and maturation

Bone marrow cells were cultured for 5 days in DC medium (RPMI 1640 medium with 10% FBS, 2 mM L-glutamine, 50 μM β-mercaptoethanol, antibiotics) in the presence of mouse GM-CSF (1000 U/ml) and IL-4 (500 U/ml), as described [34]. GM-CSF and IL-4 were replenished on day 2 and 4. On day 5, cells were collected and transferred onto a new plate with DC medium and stimulated with lipopolysaccharide (100 ng/ml; Sigma), CpG oligodeoxynucleotide 1826 (10 μg/ml), and CT-26 lysate (100 μg/ml) for 2 days to induce maturation. On day 7, DCs were collected for use as vaccines.

Tumor growth and survival

To measure tumor growth, CT-26 cells (5 × 10^5 cells in 100 μl of PBS) were injected s.c. into the right flank of Balb/c mice (n = 8) on day −3. On days 0 and 1, 5-FU (100 μg/100 μl) was injected s.c. into Balb/c mice. On day 2, mice were treated with four injections of WKYMVm (100 μg/100 μl) and mDCs (1 × 10^6 cells) at 12 h-intervals. On days 4 and 5, 5-FU (100 μg/100 μl) was injected s.c. into Balb/c mice. Subsequently, the mice were treated with s.c. injection of 5-FU, mDCs and WKYMVm once weekly for 4 weeks. Tumor volume was determined by the following formula: tumor volumes (in mm^3) = length (mm) × width (mm)^2/2.

Figure 6. Anti-metastasis activity of WKYMVm, 5-FU, and mDCs. (A) Balb/c mice were inoculated with CT-26 cells and treated with WKYMVm, 5-FU, and mDCs according to the protocol in Fig. 1A. CD8 T cells or NK cells were depleted by injecting 100 μg of anti-CD8 or anti-asialoGM1 antibody i.p. into Balb/c mice. On day 42, mice were sacrificed and tumor nodules on the surface of the lungs were observed. (B) CT-26 cells (2 × 10^6 cells in 100 μl of PBS) were injected into the tail vein of Balb/c mice. After 14 days, mice were sacrificed and hematoxylin and eosin staining was performed using the isolated lungs. The images shown are representative of eight independent experiments. *P < 0.01, **P < 0.01 compared with the control. doi:10.1371/journal.pone.0030522.g006
In addition to monitoring tumor growth, mice were observed for survival following tumor inoculation and treatment. Hematoxylin and eosin and immunofluorescence staining

Mice were euthanized 42 days after tumor inoculation, and tumors were surgically excised, fixed for 24 h in 10% neutral phosphate buffered formalin (NBF), embedded in paraffin, and sectioned and stained with hematoxylin and eosin for morphological analysis. For immunostaining, the following primary antibodies were used: anti-mouse Fas (Santa Cruz), anti-mouse cleaved caspase-3 (Cell Signaling), FITC-conjugated anti-mouse CD3 (BD Pharmingen), PE-conjugated anti-mouse CD4 (BD Pharmingen), PE-conjugated anti-mouse CD8 (BD Pharmingen), FITC-conjugated anti-mouse CD11b (BD Pharmingen), and PE-conjugated anti-mouse DX5 (BD Pharmingen) antibody. For confocal microscopy, fixed tumor tissues were stained with FITC-conjugated anti-mouse IgG and Alexa 594-conjugated anti-mouse IgG (BD Pharmingen).

In situ TUNEL staining

Terminal deoxy-nucleotidyl transferase-mediated digoxigenin-dUTP nick end labeling (TUNEL) was performed to detect apoptotic cells in the tumor tissues. Paraffin sections were deparaffinized, hydrated, treated with 3% H2O2 for 5 min, and rinsed with PBS for 15 min, and the In situ Death Detection Kit, POD, was used (Roche, Penzberg, Germany). Briefly, digoxigenin-dUTP end-labeled DNA was detected with anti-digoxigenin-peroxidase antibody followed by peroxidase detection with diaminobenzidine (DAB). Tissues were counterstained with Mayer’s hematoxylin.

Enzyme-linked immunosorbent assay (ELISA)

On day 42, blood was collected from the heart of mice and clarified by centrifugation. The serum was stored at 2–8°C until ready for cytokine analysis. Murine IL-12 (p70) and IFN-γ concentrations were measured using a standardized sandwich ELISA method (BD Biosciences Pharmingen).
**In vivo immune cell subset depletion**

To deplete CD4, CD8 T cells and NK cells, mice were treated with the corresponding antibody on days −1, 0, and 5 (where day 0 is the day of primary tumor inoculation). The monoclonal rat anti-mouse CD4 (clone GK1.5), rat anti-mouse CD8 (clone 53-6.7) and rat anti-mouse asialoGM1 antibodies were used for immuno-depletion. In the leukocyte depletion studies, 100 μg of anti-CD4, anti-CD8, or anti-asialoGM1 antibody was injected i.p. into Balb/c mice.

**Lung metastasis**

For the heterotopic lung metastasis experiment, CT-26 cells (5 × 10^5 cells in 100 μl of PBS) were injected s.c. into the right flank of Balb/c mice. On day 21, immunized mice were sacrificed and CD8 T cells or NK cells were isolated using CD8 T cell isolation kit or NK cell isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from their spleen. For adoptive therapy, tumors were established by s.c. injecting 5 × 10^6 CT26 tumor cells on the right flank of Balb/c mice. Palpable tumors (>5 mm in diameter) were administered for 5 weeks, as described above for the experiment to measure tumor volume. On day 42, mice were administered for 3 weeks, as described above for the experiment to measure tumor volume. On day 42, mice were sacrificed, and CD8 T cells or NK cells were isolated using CD8 T cell isolation kit or NK cell isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) from their spleen. For adoptive therapy, tumors were established by s.c. injecting 5 × 10^6 CT26 tumor cells on the right flank of Balb/c mice. Palpable tumors (>5 mm in diameter) were administered for 5 weeks, as described above for the experiment to measure tumor volume. On day 42, mice were treated with the corresponding antibody on days −1, 0, and 5 (where day 0 is the day of primary tumor inoculation). The monoclonal rat anti-mouse CD4 (clone GK1.5), rat anti-mouse CD8 (clone 53-6.7) and rat anti-mouse asialoGM1 antibodies were used for immuno-depletion. In the leukocyte depletion studies, 100 μg of anti-CD4, anti-CD8, or anti-asialoGM1 antibody was injected i.p. into Balb/c mice.
33. Henry CJ, Ornelles DA, Mitchell LM, Braza-Lewis KL, Hiltbold EM. (2008) IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 181: 8576–8584.

34. Talmor M, Mirza A, Turley S, Mellman I, Hoffman LA, et al. (1998) Generation of large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur J Immunol 28: 811–817.

35. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, et al. (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57: 4803–4810.